PDS Biotechnology News

Express News | Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology

BenzingaMay 9 11:12 ET

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets

GlobeNewswireMay 9 08:00 ET

Buy Rating Affirmed on PDS Biotechnology's Promising HNSCC Treatment Developments

TipRanksMay 9 06:38 ET

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets

GlobeNewswireMay 7 08:00 ET

PDS Biotechnology Announces Details of Virtual KOL Event

PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets

GlobeNewswireMay 3 08:00 ET

PDS Biotech: Toutain's Appointment Effective From May 1 >PDSB

PDS Biotech: Toutain's Appointment Effective From May 1 >PDSB

Dow JonesMay 2 08:01 ET

Express News | PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

ReutersMay 2 08:00 ET

PDS Biotechnology Welcomes Stephan Toutain as New COO

TipRanksMay 2 06:22 ET

Express News | PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer

Moomoo 24/7Apr 23 08:01 ET

PDS Biotechnology Corporation's (NASDAQ:PDSB) Market Cap Dropped US$1.5m Last Week; Individual Investors Who Hold 59% Were Hit as Were Institutions

Yahoo FinanceMar 30 08:35 ET

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 28 10:15 ET

Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)

TipRanksMar 28 08:25 ET

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating.

MT NewswiresMar 28 07:57 ET

PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success

TipRanksMar 28 07:25 ET

Q4 2023 PDS Biotechnology Corp Earnings Call

Yahoo FinanceMar 27 23:33 ET

Earnings Call Summary | PDS Biotechnology(PDSB.US) Q4 2023 Earnings Conference

The following is a summary of the PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript:Financial Performance:PDS Biotechnology Corporation reported a net loss of approximately $42.9 m

moomoo AIMar 27 12:35 ET · Conference Call

PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.

PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 27 10:39 ET

PDS Biotechnology: A Strong Buy on Strategic Focus and Promising HNSCC Trial Data

TipRanksMar 27 10:35 ET

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Maintains $21 Price Target

HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology with a Buy and maintains $21 price target.

Analyst UpgradesMar 27 10:28 ET

PDS Biotechnology Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 459.25% HC Wainwright & Co. $21 → $21 Maintains Buy 11/15/2023 432.62% Oppenheimer $23 → $20 Ma

BenzingaMar 27 10:27 ET